Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and $535 price target Stay Ahead of the Market: ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

For his part, Natan Nakel, Creative Coordinator at Control F5, spearheaded the rebranding process, creating a visual identity ...

Vertex has doubled down on cell-based therapies ... or possibly even stop taking insulin to keep their blood sugar under control. ViaCyte has been working on the development of its own CRISPR ...

Vertex said it intends to move suzetrigine into phase 3 in painful LSR "pending discussions with regulators." Changes to trial design may be able to "better control the placebo response and ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

PETAH TIKVA, Israel, April 17, 2025 /PRNewswire/ -- Elmo Motion Control, a global technology leader in motion control solutions, announces the launch of the Titanium Maestro, the next-generation ...